The Review Panel (MHRA)

The Review Panel (MHRA) carries out statutory and non-statutory reviews of proposals, decisions and provisional decisions taken by Medicines and Healthcare Products Regulatory Agency.

Role of the group

The terms of reference for the Review Panel (MHRA) are to:

  • review the provisional determinations made by the Medicines and Healthcare Products Regulatory Agency (MHRA) concerning the classification of a product as a medicine
  • perform the role of the ‘reviewers’ in relation to decisions or proposals made by the MHRA related to the grant, renewal, revocation, suspension, refusal or variation of manufacturer’s or wholesale dealing licences, and UK marketing authorisations (the ‘persons appointed’ role)
  • consider representations about decisions made in relation to advertising

The Review Panel became a departmental expert committee on 1 November 2012 as a result of the Arm’s Length Body (ALB) Review in 2010.

The Code of Practice

Code of Practice on conflicts of interest applies to chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees.  See Code of Practice.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

Current vacancies

Please contact Committee Services - Recruitment Team if you are interested in joining the Review Panel at CSTRecruitment@mhra.gov.uk.

Annual report

Members

Post Name Affiliations
Chair Dr Adam Hacker BA (Hons), MA, PhD Director and Global Head of Regulatory Affairs and Quality, Coalition of Epidemic Preparedness Innovations (CEPI)
Lay Member Mrs Rachelle Broadley JP MA (Cantab) Solicitor, Macmillan Cancer Support
Member Dr Zainab Rai BSc, MBBS, MRCS, PG Dip. General Surgical Registrar and Honorary Clinical Fellow, University College London Hospital
Member Dr Susan Shelmerdine MBBS(Dist), BSc(hons), MRCS, PGCert HBE, FHEA, FRCR, PhD Consultant Paediatric Radiologist, Great Ormond Street Hospital for Children NHS Foundation Trust. Honorary Associate Professor, Population, Policy and Practice. UCL Great Ormond Street Institute of Child Health.

Reviewers (participation at specific appeals only) appointed under Sch 5 para 2 of the Human Medicines Regulations 2012 (as amended):

  • Dr Alan Fayaz MD(Res) MRCP FRCA FFPMRCA (University College London Hospital NHS Foundation Trust)
  • Dr Roger Knaggs BSc BMedSci PhD EDPM FFRPS FRPharmS FFPMRCA (University of Nottingham and Primary Integrated Community Solutions
  • Dr Matt Mulvey BSc (Hons) PhD (University of Leeds)
  • Dr Paul Farquhar-Smith MA, MB BChir, MA, PhD, FRCA, FFPMRCA (The Royal Marsden NHS Foundation Trust)
  • Professor Michael D Threadgill PGCE MA PhD DSc FRSC CChem (University of Bath and Aberystwyth University)